AD Pipeline Watch: First Patient Enrolled in Phase 2b Trial of Evommune’s Oral MRGPRX2 Antagonist
The first patient has been enrolled in a Phase 2b trial of Evommune, Inc.’s EVO756, an oral small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2), that targets moderate-to-severe atopic dermatitis (AD).